Executive Leadership Changes - Mollie Leoni, MD, promoted to Chief Medical Officer after serving as Executive Vice President of Clinical Development and clinical lead for the ziftomenib program since 2020 [1] - Francis Burrows, PhD, promoted to Chief Scientific Officer after leading translational research efforts for the past nine years [1] - Stephen Dale, MD, steps down as Chief Medical Officer and Head of R&D to prioritize personal health, effective January 2, 2025 [1] Leadership Contributions and Expertise - Stephen Dale played a key role in advancing ziftomenib through a first registration-enabling study and laying the foundation for KO-2806 as a combination partner across solid tumor indications [2] - Mollie Leoni has a robust background in oncology and orphan drug development, previously leading clinical efforts for mogamulizumab at Kyowa Kirin, which achieved international registration for cutaneous T-cell lymphoma [2] - Francis Burrows has over 20 years of experience in drug discovery and development, focusing on cancer biology and small molecule drugs, and founded two biotech startups, including Conforma Therapeutics, acquired by Biogen in 2006 [3] Company Overview and Pipeline - Kura Oncology is a clinical-stage biopharmaceutical company focused on precision medicines for cancer treatment, with a pipeline of small molecule drug candidates targeting cancer signaling pathways [4] - Ziftomenib, a once-daily oral menin inhibitor, is the first investigational therapy to receive Breakthrough Therapy Designation from the FDA for relapsed/refractory NPM1-mutant AML [4] - Kura entered a global strategic collaboration with Kyowa Kirin in November 2024 to develop and commercialize ziftomenib for AML and other hematologic malignancies [4] - Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, with a New Drug Application anticipated in 2025 [5] - KO-2806, a next-generation farnesyl transferase inhibitor, is in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies [5] - Tipifarnib, a selective FTI, is in a Phase 1/2 trial in combination with alpelisib for PIK3CA-dependent head and neck squamous cell carcinoma [5]

Kura Oncology, Inc. (NASDAQ: KURA ) is a clinically staged biopharma, established in 2014 and headquartered in San Diego, California. The company focuses exclusively on the development of small-molecule drugs that are informed by patient selection biomarkers, also known asBrendan, a Pennsylvanian by birth:-Completed a Ph.D. at Stanford University in the field of organic synthesis (2009). -Worked for a major pharmaceutical company (Merck, 2009-2013).-Worked in biotech including start-ups (Theravance/Aspira) ...

Kura Oncology, Inc. (NASDAQ:KURA) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Pete De Spain - Head, Investor Relations Dr. Troy Wilson - President and CEO Tom Doyle - Senior Vice President, Finance and Accounting Dr. Mollie Leoni - Executive Vice President, Clinical Development Conference Call Participants Li Watsek - Cantor Jonathan Chang - Leerink Partners Jason Zemansky - Bank of America Roger Song - Jefferies Charles Zhu - LifeSci Capital Phil Nadeau - TD Cowen Pete ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission File Number: 001-37620 KURA ONCOLOGY, INC. (Exact name of registrant as specified in its charter) Delaware 61-1547851 (Sta ...

Exhibit 99.1 Kura Oncology Reports Third Quarter 2024 Financial Results – Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a dose-escalation study of ziftomenib combined with ven/aza in R/R AML and 7+3 in 1L adverse risk AML to be presented at ASH – – Phase 1b expansion study of ziftomenib in combination with standards of care now enrolling at 600 mg in all cohor ...

SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2024 financial results after the close of U.S. financial markets on Thursday, November 7, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate ...

– Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive (1L) and imatinib-resistant (2L/3L) GIST models – – Proof-of-concept study of ziftomenib plus imatinib in patients with advanced GIST after imatinib failure to begin in 1H 2025 – SAN DIEGO, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported ...

SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the publication of its KOMET-001 Phase 1 study manuscript in The Lancet Oncology journal. The paper, entitled "Ziftomenib in relapsed/refractory acute myeloid leukaemia (KOMET-001): results from an open-label, multi-cohort, phase 1a/1b trial," is now available on The Lancet Oncology ...

SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership. "On behalf of our Board and leadership team, we are delig ...

Kura Oncology, Inc. (NASDAQ:KURA) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants Pete De Spain - Head, IR Troy Wilson - President and CEO Thomas Doyle - SVP of Finance and Accounting Conference Call Participants Li Watsek - Cantor Fitzgerald Jonathan Chang - Leerink Partners Cameron Bozdog - Bank of America Roger Song - Jefferies Brad Canino - Stifel Phil Nadeau - TD Cowen Alex Bouilloux - Barclays Justin Zelin - BTIG George Farmer - Scotiabank Operator Good day, and welcome ...